Outset Medical Reports Mixed Q4 Results, Shares Decline After Hours
Medical technology company Outset Medical Inc (NASDAQ:OM) released its fourth quarter and full-year 2025 financial results after the market close on Tuesday, February 11. The report presented a complex picture of progress on profitability against a backdrop of modest revenue growth, leading to a negative reaction in after-hours trading.
Earnings and Revenue Versus Estimates
The company's performance relative to Wall Street expectations was mixed. Outset Medical reported a net loss of $19.5 million for the quarter, which translated to a non-GAAP net loss of $15.1 million. On a per-share basis, the non-GAAP loss was $0.84.
- Non-GAAP EPS: Reported at -$0.84, missing the analyst consensus estimate of -$0.66.
- Revenue: Reported at $28.9 million, surpassing the analyst estimate of $27.4 million.
This divergence—a revenue beat coupled with a larger-than-expected loss—appears to be a key driver of the immediate market reaction. Following the release, the stock was down approximately 5.7% in after-hours trading.
Full-Year 2025 and Forward Guidance
For the full year 2025, the company reported revenue of $119.5 million, a 5% increase over 2024. Management provided guidance for 2026, projecting revenue in the range of $125 million to $130 million. This outlook represents a year-over-year growth rate of 5% to 9%.
- 2026 Revenue Guidance: $125M - $130M (Company Provided)
- 2026 Revenue Estimate: $131.5M (Analyst Consensus)
The company's guidance range, while demonstrating expected growth, falls slightly below the current analyst consensus estimate of approximately $131.5 million for the full year 2026. This conservative forecast may have contributed to investor caution.
Key Operational and Financial Highlights
Beyond the headline earnings figures, the press release highlighted several significant operational and financial improvements that management emphasized as building a foundation for future growth.
- Margin Expansion: Gross margin showed substantial improvement, expanding to 42.4% in Q4 2025 from 36.5% in the prior-year period. For the full year, gross margin improved more than 500 basis points to 39.1%.
- Cost Discipline: Operating expenses for the quarter declined by 8% year-over-year to $29.9 million, reflecting cost-reduction initiatives. For the full year, operating expenses were reduced by 25%.
- Improved Cash Burn: Net cash used in operating activities was $46 million for 2025, a significant improvement from $116 million in 2024.
- Strong Liquidity: The company ended the year with $173 million in total cash, cash equivalents, and short-term investments.
- Product Development: Outset received FDA clearance for its next-generation Tablo platform, which is designed with enhanced cybersecurity and connectivity features and is expected to launch in the second quarter of 2026.
Market Reaction and Path Forward
The negative after-hours price action suggests investors are weighing the near-term earnings miss and cautious 2026 revenue outlook against the clear operational progress on margins and cost control. The market's reaction indicates a focus on the bottom-line shortfall in the quarter, despite the top-line beat.
Chair and CEO Leslie Trigg struck an optimistic tone, stating, “We enter 2026 standing on a strong foundation for growth, well capitalized, and with a highly differentiated platform to help healthcare providers transform their clinical, operational and financial outcomes by insourcing dialysis with Outset.”
The company’s ability to continue its margin expansion trajectory, successfully launch its next-generation Tablo system, and accelerate revenue growth towards the higher end of its guidance range will likely be critical factors for investor sentiment moving forward.
For a detailed look at upcoming earnings dates and analyst estimates, you can review the earnings and estimates page for Outset Medical here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.